Multiple sclerosis: Expression of CDIa and production of IL-12 p70 and IFN-γ by blood mononuclear cells in patients on combination therapy with IFN-β and glatiramer acetate compared to monotherapy with IFN-β

Multiple Sclerosis

Volumn 10, Issue 1, 2004, Pages 16-25

  Hussein, Yassir ^a   Sanna, Alessandra ^a,b   Söderström, Mats ^a,c   Link, Hans ^a,c   Huang, Yu Min ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SASSARI   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CDIa; Glatiramer acetate; IFN ; IFN ; IL 12p70; Multiple sclerosis

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; BETA1A INTERFERON; CD1 ANTIGEN; CD86 ANTIGEN; CELL SURFACE PROTEIN; GAMMA INTERFERON; GLATIRAMER; GLYCOLIPID; HLA DR ANTIGEN; INTERLEUKIN 12; T6 ANTIGEN;

ARTICLE; CELL ACTIVATION; CELL SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW UP; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MONOTHERAPY; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TH1 CELL; TH2 CELL;

ADULT; ANTIGENS, CD1; ANTIGENS, CD80; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; PEPTIDES; PROTEIN SUBUNITS;

EID: 0347968011     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms979oa     Document Type: Article

References (22)

1. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
2. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999; 46: 197-206.
3. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50: 701-708.
4. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - Measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-97.
5. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, Tuohy VK. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50; 1294-1300.
6. Huang YM, Hussien Y, Yarilin D, Xiao BG, Liu YJ, Link H. Interferon-beta induces the development of type 2 dendritic cells. Cytokine 2001; 13: 264-71.
7. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82 - 100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. PNAS (USA) 1999; 96: 634-39.
8. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-708.
9. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47: 127-31.
10. Porcelli SA, Modlin RL. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999; 17: 297-329.
11. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995; 80: 707-18.
12. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-95.
13. Van Boxel-Dezaire AH, Hoff SC, Van Oosten BW, Verweij CL, Drager AM, Ader HJ et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 6: 695-703.
14. Huang YM, Kouwenhoven M, Jin YP, Press R, Huang WX, Link H. Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult Scler 2001; 7: 95-99.
15. Hussien Y, Sanna A, Soderstrom M, Link H, Huang YM. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001; 121: 102-10.
16. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
17. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999; 29: 1667-75.
18. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI et al. B7-DC, a new dendritic cell molecule with potent co-stimulatory properties for T cells. J Exp Med 2001; 193: 839-46.
19. Cua D, Sherlock J, Chen Y, Murphy C, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein R, Sedgwick J. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-48
20. Watford WT, O'Shea JJ. A case of mistaken identity. Nature 2003; 421: 706-708.
21. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879-84.
22. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implication for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.